PCSK9 and LDLR degradation

Plasma proprotein convertase subtilisin–kexin type 9 is predominantly related to intermediate density lipoproteins

(2014) Arjan J. Kwakernaak et al.   CLINICAL BIOCHEMISTRY

Isolation and characterization of the circulating truncated form of PCSK9

(2014) Bomie Han et al.   JOURNAL OF LIPID RESEARCH

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

(2014) Frederick J. Raal et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

(2014) Dirk J. Blom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation

(2014) Hong-Bo Xiao et al.   Pharmacological Reports

Transintestinal Cholesterol Excretion Is an Active Metabolic Process Modulated by PCSK9 and Statin Involving ABCB1

(2013) Cédric Le May et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor

(2013) Hagai Tavori et al.   CIRCULATION

Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

(2013) Evan A. Stein et al.   Current Atherosclerosis Reports

The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions

(2013) Nabil G. Seidah et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation

(2013) Tanja Kosenko et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy

(2013) Frederick Raal et al.   Journal of the American Heart Association

Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor

(2012) Hua Sun et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice

(2012) Ding Ai et al.   JOURNAL OF CLINICAL INVESTIGATION

PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population

(2012) Iris Postmus et al.   JOURNAL OF LIPID RESEARCH

Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies

(2012) Wijtske Annema et al.   Nutrition & Metabolism

Crosstalk between reverse cholesterol transport and innate immunity

(2012) Kathleen M. Azzam et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor

(2011) Øystein L. Holla et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome

(2011) Caroline Richard et al.   BRITISH JOURNAL OF NUTRITION

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans

(2010) Lena Persson et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control

(2010) Bronwen Herbert et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

In VivoEvidence That Furin from Hepatocytes Inactivates PCSK9

(2010) Rachid Essalmani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effects of the Prosegment and pH on the Activity of PCSK9

(2010) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

(2010) Jeffrey D. Browning et al.   JOURNAL OF LIPID RESEARCH

Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters

(2010) Bin Dong et al.   JOURNAL OF LIPID RESEARCH

Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis

(2010) Shijie Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis

(2009) Angela D Armendariz et al.   CURRENT OPINION IN LIPIDOLOGY

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

(2009) Marianne Abifadel et al.   HUMAN MUTATION

Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine

(2009) Hai Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

(2009) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of the Liver X Receptor Stimulates Trans-intestinal Excretion of Plasma Cholesterol

(2009) Jelske N. van der Veen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

(2009) J. C. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inflammation stimulates the expression of PCSK9

(2008) Kenneth R. Feingold et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Regulation of ApoB Secretion by the Low Density Lipoprotein Receptor Requires Exit from the Endoplasmic Reticulum and Interaction with ApoE or ApoB

(2008) Daniel A. Blasiole et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Plasma PCSK9 preferentially reduces liver LDL receptors in mice

(2008) Aldo Grefhorst et al.   JOURNAL OF LIPID RESEARCH

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA